The FDA has expanded the indication of Rinvoq to include active, polyarticular juvenile idiopathic arthritis and psoriatic arthritis in children aged 2 years and older, according to an AbbVie press release.
The announcement represents the first indication of Rinvoq (upadacitinib, AbbVie) for pediatric patients aged 2 years and older, the company said. To use the drug under the new indication,